Grundläggande statistik
| LEI | 969500U8ZZCODU8A9374 |
| CIK | 1624422 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Erytech Pharma
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| March 11, 2024 |
EX-99.1 Exhibit 99.1 PRESS RELEASE PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces |
|
| March 11, 2024 |
15F-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15F CERTIFICATION OF A FOREIGN PRIVATE ISSUER’S TERMINATION OF REGISTRATION OF A CLASS OF SECURITIES UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ITS TERMINATION OF THE DUTY TO FILE REPORTS UNDER SECTION 13(a) OR SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38281 |
|
| March 4, 2024 |
As filed with the Securities and Exchange Commission on March 4, 2024 As filed with the Securities and Exchange Commission on March 4, 2024 Registration No. |
|
| March 4, 2024 |
As filed with the Securities and Exchange Commission on March 4, 2024 As filed with the Securities and Exchange Commission on March 4, 2024 Registration No. |
|
| March 4, 2024 |
As filed with the Securities and Exchange Commission on March 4, 2024 As filed with the Securities and Exchange Commission on March 4, 2024 Registration No. |
|
| March 4, 2024 |
As filed with the Securities and Exchange Commission on March 4, 2024 As filed with the Securities and Exchange Commission on March 4, 2024 Registration No. |
|
| March 4, 2024 |
As filed with the Securities and Exchange Commission on March 4, 2024 As filed with the Securities and Exchange Commission on March 4, 2024 Registration No. |
|
| March 4, 2024 |
As filed with the Securities and Exchange Commission on March 4, 2024 As filed with the Securities and Exchange Commission on March 4, 2024 Registration No. |
|
| March 1, 2024 |
25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38281 PHAXIAM Therapeutics S.A. The Nasdaq Capital Market (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) |
|
| February 21, 2024 |
Exhibit 99.1 PRESS RELEASE PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market •PHAXIAM remains listed on Euronext Paris as its primary trading market •Nasdaq delisting will significantly reduce PHAXIAM’s cash utilization and enable the Company to focus its financial resources on key development and value milestones Lyon (France) a |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-38281 PHAXIAM Therapeutics S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive |
|
| January 19, 2024 |
Exhibit 99.1 PRESS RELEASE PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024 Lyon (France) and Cambridge (MA, US), January 18, 2024, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces its cash position as of |
|
| January 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2024 Commission File Number: 001-38281 PHAXIAM Therapeutics S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive |
|
| November 16, 2023 |
Exhibit 99.1 PRESS RELEASE PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023 Conference call and webcast (English) on Wednesday, November 15, 2023 at 8:30am ET / 2:30pm CET •Ambitious clinical development strategy progressing to create a global phage therapy leader in high-value indications •Early access program continues to gain momentum with the treatment of more than |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-38281 PHAXIAM Therapeutics S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive |
|
| October 25, 2023 |
Exhibit 99.2 PRESS RELEASE PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus •Approval of study design by French ANSM and Ethics Committee •Recruitment of 12 patients expected to start in Q4 2023 in 4 French centers •First study results expected in mid-2024 Lyon (France) et Cambridge (MA, US), October 24, 2023, at 10: |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 Commission File Number: 001-38281 PHAXIAM Therapeutics S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive |
|
| October 25, 2023 |
TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation Exhibit 99.1 PRESS RELEASE TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation Lyon (France) et Cambridge (MA, US), October 23, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for resistant bacterial infections, today announced that TP ICAP Midcap, a brokerage firm and investment |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 Commission File Number: 001-38281 PHAXIAM Therapeutics S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive |
|
| October 11, 2023 |
Exhibit 99.1 PRESS RELEASE PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains Data from PHAXIAM’s phagogram, first CE-marked Phage Susceptibility Test (PST), showed 98% response rate over 105 clinical S. aureus strains Lyon (France) et Cambridge (MA, US), October 9, 2023 at 10:05pm CEST – PHAXIAM Therapeutics (Nasdaq & Eurone |
|
| October 5, 2023 |
PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration Exhibit 99.1 PRESS RELEASE PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration •Strategic research partnership between PHAXIAM Therapeutics and Vetophage, a biotechnology company specialized in veterinary phage therapy •Combining expertise in the research of new phages and phage endolysins that could be applied to human health •Exclusive phage and endolysin licensing optio |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 Commission File Number: 001-38281 PHAXIAM Therapeutics S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive |
|
| October 5, 2023 |
PHAXIAM Receives Compliance Notice from Nasdaq Exhibit 99.2 PRESS RELEASE PHAXIAM Receives Compliance Notice from Nasdaq Lyon (France) et Cambridge (MA, US), October 4, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announced that it has received confirmation from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2). With closing bid price of PHAXIAM’s American Depositary Shares (“ADSs”) above $1. |
|
| September 26, 2023 |
Exhibit 99.2 PRESS RELEASE PHAXIAM Provides Business and Financial Update For the First Half of 2023 Conference call and webcast (English) on Monday, September 25, 2023 at 8:30am ET / 2:30pm CEST ▪Formation of PHAXIAM Therapeutics effective as of June 23, 2023, to create a global leader in phage therapies for high-value indications ▪Ambitious strategy to develop value-creating clinical and regulat |
|
| September 26, 2023 |
I.CERTIFICATION OF THE PERSON RESPONSIBLE FOR THE HALF-YEAR FINANCIAL REPORT I.CERTIFICATION OF THE PERSON RESPONSIBLE FOR THE HALF-YEAR FINANCIAL REPORT “I hereby certify that, to my knowledge, the condensed consolidated financial statements for the six-month period ended June 30, 2023 were prepared in accordance with applicable accounting principles and give a fair view of assets, financial position and results of the Company and all companies included in the scope of co |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-38281 PHAXIAM Therapeutics S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executiv |
|
| September 21, 2023 |
Exhibit 99.1 PRESS RELEASE PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target ◦Klebsiella pneumoniae is responsible for severe infections and stands out for its high resistance to antibiotics ◦PHAXIAM's anti-Klebsiella pneumoniae phages to enter pre-clinical development to assess their efficacy in lung, blood and urinary tract |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-38281 PHAXIAM Therapeutics S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executiv |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-38281 PHAXIAM Therapeutics S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executiv |
|
| September 18, 2023 |
PHAXIAM Therapeutics announces the completion of its reverse share split Exhibit 99.1 PRESS RELEASE PHAXIAM Therapeutics announces the completion of its reverse share split • Reverse share split through the exchange of ten (10) existing shares with a par value of ten euro cents (€0.10) for one (1) new share with a par value of one euro (€1). • Effective date of reverse share split (listing of new shares): September 18th, 2023 Lyon (France) and Cambridge (MA, US), Septe |
|
| September 15, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-38281 PHAXIAM Therapeutics S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal exec |
|
| September 7, 2023 |
Exhibit 99.1 PRESS RELEASE PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences Lyon (France) and Cambridge (MA, US), September 5, 2023 – 10:05 p.m. CEST - PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) (the "Company"), today publishes its cash position as of June 30, 2023, and its financial calendar for the s |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-38281 PHAXIAM Therapeutics S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executiv |
|
| July 27, 2023 |
PHAXIAM Therapeutics announces a reverse share split of its shares EX-99.1 Exhibit 99.1 PRESS RELEASE PHAXIAM Therapeutics announces a reverse share split of its shares Reverse share split by the exchange of ten (10) existing shares with a par value of ten-euro cents (€0.10) for one (1) new share with a par value of one euro (€1) Publication of the reverse share split notice in the BALO: July 31st, 2023 Start of the reverse share split: August 16th, 2023 Effectiv |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-38281 PHAXIAM Therapeutics S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive off |
|
| June 30, 2023 |
Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM Exhibit 99.1 PRESS RELEASE Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM Lyon (France) and Cambridge (MA, US), June 28, 2023 - Phaxiam Therapeutics (Nasdaq & Euronext: FR0011471135), announces change of the mnemonic code of its share from ERYP to PHXM, following the merger between ERYTECH and PHERECYDES. The change has been notified by Euronext and will be effec |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38281 PHAXIAM Therapeutics S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive off |
|
| June 29, 2023 |
Rule 424(b)(3) File No. 333-201279 Note: ERYTECH Pharma S.A. has changed its name to PHAXIAM Therapeutics S.A. effective June 29, 2023. EXHIBIT A AMERICAN DEPOSITARY SHARES (Each American Depositary Share represents one deposited Share) THE BANK OF NEW YORK MELLON AMERICAN DEPOSITARY RECEIPT FOR ORDINARY SHARES OF PHAXIAM THERAPEUTICS S.A. (INCORPORATED UNDER THE LAWS OF FRANCE) The Bank of New Yo |
|
| June 28, 2023 |
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics Exhibit 99.2 PRESS RELEASE ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics •Merger approved with large majority by the shareholders of both companies •New governance structure implemented •Ambition to create a global leader in extended phage therapies to target antimicrobial resistant pathogenic bacteria Lyon (France) and Cambridge (MA, US), June 26, 2023 – ERYTECH ( |
|
| June 28, 2023 |
Exhibit 99.1 PRESS RELEASE ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023 •All resolutions voted with a large majority according to Board of Directors recommendations •Company renamed Phaxiam Therapeutics, creating a world leader in phage therapy Lyon (France), June 23, 2023 – ERYTECH Pharma (Euronext |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38281 PHAXIAM Therapeutics S.A. (formerly ERYTECH Pharma S.A.) (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Add |
|
| June 21, 2023 |
Exhibit 99.1 PRESS RELEASE ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit Cambridge, MA (U.S.) and Lyon (France), June 20, 2023 – ERYTECH Pharma (Euronext Paris and Nasdaq: ERYP) announces the filing of a new lawsuit by Akkadian Partners. Despite the rejection by the President of the Lyon Commercial Court of Akkadian Partners' request |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) I |
|
| June 15, 2023 |
Exhibit 99.1 PRESS RELEASE ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma Cambridge, MA (U.S.) and Lyon (France), June 14, 2023, 8:00 pm CEST – ERYTECH Pharma (Nasdaq & Euronext: ERYP), announced today that the Lyon Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecyd |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) I |
|
| June 12, 2023 |
ERYTECH Responds to Akkadian’s Disinformation Exhibit 99.1 PRESS RELEASE ERYTECH Responds to Akkadian’s Disinformation ▪Akkadian’s challenge of the merger is based on incomplete information and misleading arguments ▪Akkadian has not presented any valuable alternative option ▪Akkadian’s unfounded actions present a risk of destruction of shareholder value and loss of employment at two companies, and the potential loss of a strategically importa |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) I |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) I |
|
| June 6, 2023 |
Exhibit 99.1 PRESS RELEASE ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes Cambridge, MA (U.S.) and Lyon (France), June 5, 2023 – ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Akkadian |
|
| May 26, 2023 |
Exhibit 99.1 PRESS RELEASE ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023 Cambridge, MA (U.S.) and Lyon (France), May 24, 2023 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the a |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) In |
|
| May 24, 2023 |
CB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form CB TENDER OFFER/RIGHTS OFFERING NOTIFICATION FORM Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to file this Form: Securities Act Rule 801 (Rights Offering) ☐ Securities Act Rule 802 (Exchange Offer) ☒ Exchange Act Rule 13e-4(h)(8) (Issuer Tender Offer) ☐ Exchange Act Rule |
|
| May 24, 2023 |
EX-99.1 Exhibit 99.1 MERGER-ABSORPTION OF BY EXEMPTION DOCUMENT PREPARED IN CONNECTION WITH THE MERGER BY ABSORPTION OF PHERECYDES PHARMA BY ERYTECH PHARMA This exemption document (the “Exemption Document”) is available free of charge at the registered office of Erytech Pharma (60 Avenue Rockefeller, 69008 Lyon, France) and on its website (http://www.erytech.com/). The Exemption Document is also a |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) In |
|
| May 24, 2023 |
F-X UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A. Name of issuer or person filing (“Filer”): ERYTECH Pharma S.A. B. (1) This is (check one): ☒ original filing for the Filer ☐ amended filing for the Filer (2) Check the following box if you are filing the Form F-X in paper in accordance with Regulation |
|
| May 24, 2023 |
EX-99.2 Exhibit 99.2 PHERECYDES PHARMA Limited company (société anonyme) with a Board of Directors and capital of €7,939,179 Registered office: 22, Boulevard Benoni Goullin – 44200 Nantes, France 493 252 266 Nantes Trade and Companies Register 2022 ANNUAL FINANCIAL REPORT 1 STATEMENT BY THE PERSON RESPONSIBLE FOR THE 2022 ANNUAL FINANCIAL REPORT (Article 222-3-4° of the AMF General Regulation) “I |
|
| May 16, 2023 |
ERYTECH Provides Update on the Announced Combination with PHERECYDES Exhibit 99.1 PRESS RELEASE ERYTECH Provides Update on the Announced Combination with PHERECYDES ▪Entry into a definitive merger agreement between ERYTECH and PHERECYDES ▪Completion of a contribution in kind of PHERECYDES shares to ERYTECH ▪Combination with PHERECYDES to be submitted to shareholders' vote on June 23, 2023 Lyon (France) and Cambridge (MA, US), May 15, 2023 – ERYTECH Pharma (Nasdaq & |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) In |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) In |
|
| May 10, 2023 |
ERYTECH Provides Business and Financial Update for the First Quarter of 2023 Exhibit 99.1 PRESS RELEASE ERYTECH Provides Business and Financial Update for the First Quarter of 2023 ▪Combination with Pherecydes, intending to create a global leader in extended phage therapies to target antimicrobial resistant pathogenic bacteria to be submitted to shareholders' vote in June 2023 ▪Cash and cash equivalents of €30.5 million ($33.7 million) at the end of March 2023 Lyon (France |
|
| April 18, 2023 |
ERYTECH Announces Approval to Transfer its Listing to the Nasdaq Capital Market Exhibit 99.1 PRESS RELEASE ERYTECH Announces Approval to Transfer its Listing to the Nasdaq Capital Market Cambridge, MA (U.S.) and Lyon (France), April 17, 2023 – ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it received approval from The Nasdaq |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2023 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) |
|
| March 28, 2023 |
Exhibit 12.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULES 13a-14(a) and 15d - 14(a) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Gil Beyen, certify that: 1. I have reviewed this annual report on Form 20-F of ERYTECH Pharma S.A. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a m |
|
| March 28, 2023 |
Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 |
|
| March 28, 2023 |
Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the ordinary shares, the American Depositary Shares and the bylaws of Erytech Pharma S.A. (“Erytech” or the “Company”) is a summary and does not purport to be complete. This summary is subject to and qualified in its entirety by reference to the complete text |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 28, 2023 |
Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statements Nos. 333-265927, 333-255900, 333-239429, 333-232670, and 333-222673 on Form S-8 and Nos. 333-248953 and 333-259690 on Form F-3 of our reports dated March 28, 2023, with respect to the consolidated financial statements of Erytech Pharma S.A and the effect |
|
| March 28, 2023 |
Exhibit 12.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULES 13a - 14(a) AND 15(d)-14(a) as ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Eric Soyer, certify that: 1. I have reviewed this annual report on Form 20-F of ERYTECH Pharma S.A. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of |
|
| March 23, 2023 |
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022 Exhibit 99.1 PRESS RELEASE ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022 ▪Combination with Pherecydes announced, intending to create a global leader in extended phage therapies targeting antimicrobial resistant pathogenic bacteria ▪Deep restructuring implemented; team size reduced by approximately 75% since start of 2022 ▪Cash and cash equivalents of €38. |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2023 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2023 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive offic |
|
| February 16, 2023 |
Exhibit 99.1 PRESS RELEASE Not for distribution in the United States, Canada, Japan, Australia, South Africa, or Italy. This press release does not constitute an offer to purchase any securities ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies Conference call and webcast in English on February 16, 2023 at 8:30am EST / 02:30pm CET an |
|
| February 14, 2023 |
EYRYY / Erytech Pharma / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-eryp123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ERYTECH Pharma S.A. (Name of Issuer) American Depositary Shares, each representing one ordinary share, nominal value €0.10 per share (Title of Class of Securities) 29604W108 (CUSIP Number) December 31, 2022 (Date of |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 ERYTECH Pharma S.A. (Name of Issuer) Ordinary Shares, nominal value €0.10 per share (Title of Class of Securities) 29604W108 (CUSIP Number |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 ERYTECH Pharma S.A. (Name of Issuer) Ordinary Shares, nominal value ?0.10 per share (Title of Class of Securities) 29604W108 (CUSIP Number |
|
| November 22, 2022 |
6-K 1 eryp6-kx11212022.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Addre |
|
| November 22, 2022 |
Exhibit 99.1 PRESS RELEASE ERYTECH Provides Business and Financial Update for the Third Quarter of 2022 Conference call and webcast on Tuesday, November 22, 2022 at 8:30am ET / 02:30pm CET ?Lead program Graspa halted ?Focus on preclinical programs and partnering options ?Deep restructuring implemented; team size reduced by approximately 75% since start of year ?Cash and cash equivalents of ?47.3 m |
|
| October 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2022 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office |
|
| October 14, 2022 |
ERYTECH Announces Receipt of Nasdaq Notice Exhibit 99.1 PRESS RELEASE ERYTECH Announces Receipt of Nasdaq Notice Cambridge, MA (U.S.) and Lyon (France), October 13, 2022 – ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it received written notification (the “Notification Letter”) from The N |
|
| September 12, 2022 |
I.CERTIFICATION OF THE PERSON RESPONSIBLE FOR THE HALF-YEAR FINANCIAL REPORT ?I hereby certify that, to my knowledge, the condensed financial statements for the six-month period ended June 30, 2022 were prepared in accordance with applicable accounting principles and give a fair view of assets, financial position and results of the Company and all companies included in the scope of consolidation, |
|
| September 12, 2022 |
I.CERTIFICATION OF THE PERSON RESPONSIBLE FOR THE HALF-YEAR FINANCIAL REPORT ?I hereby certify that, to my knowledge, the condensed financial statements for the six-month period ended June 30, 2022 were prepared in accordance with applicable accounting principles and give a fair view of assets, financial position and results of the Company and all companies included in the scope of consolidation, |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2022 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive offi |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2022 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive of |
|
| August 25, 2022 |
ERYTECH Provides Regulatory Update Exhibit 99.1 PRESS RELEASE ERYTECH Provides Regulatory Update ?ERYTECH to stop further plans to pursue a BLA submission seeking an approval for Graspa? in hypersensitive ALL ?Evaluation of strategic partnering options ongoing Cambridge, MA (U.S.) and Lyon (France), August 24, 2022 ? ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies |
|
| August 25, 2022 |
6-K 1 eryp6-kx08242022.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2022 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address |
|
| June 30, 2022 |
As filed with the Securities and Exchange Commission on June 30, 2022 As filed with the Securities and Exchange Commission on June 30, 2022 Registration No. |
|
| June 30, 2022 |
EX-FILING FEES 4 d322191dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) ERYTECH Pharma S.A. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Regi |
|
| June 28, 2022 |
REPORT – ERYTECH’s combined shareholders’ meeting on June 24, 2022 Exhibit 99.1 PRESS RELEASE REPORT ? ERYTECH?s combined shareholders? meeting on June 24, 2022 Cambridge, MA (U.S.) and Lyon (France), June 24, 2022 ? ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that its Annual General Meeting was held on Frid |
|
| June 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) I |
|
| May 25, 2022 |
Exhibit 99.1 PRESS RELEASE ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022 Cambridge, MA (U.S.) and Lyon (France), May 24, 2022 ? ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the a |
|
| May 25, 2022 |
6-K 1 eryp6-kx05242022.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) In |
|
| May 13, 2022 |
Exhibit 99.1 PRESS RELEASE ERYTECH Provides Business and Financial Update for the First Quarter of 2022 Conference call and webcast on Friday, May 13, 2022 at 8:30am EDT / 02:30pm CEST ?U.S. cell therapy manufacturing facility sold to Catalent for a total consideration of USD 44.5 million ?Progress towards seeking approval of GRASPA? (BLA) for the treatment of acute lymphoblastic leukemia (ALL) pa |
|
| May 2, 2022 |
Exhibit 99.1 PRESS RELEASE ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar Cambridge, MA (U.S.) and Lyon (France), April 28, 2022 ? ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances i |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) In |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) |
|
| April 28, 2022 |
Exhibit 99.1 ASSET PURCHASE AGREEMENT by and among ERYTECH PHARMA, S.A., ERYTECH PHARMA, INC., CATALENT PRINCETON, LLC and CATALENT PHARMA SOLUTIONS, INC. (solely for purposes of Section 6.17) dated as of April 22, 2022 TABLE OF CONTENTS Page ARTICLE I DEFINED TERMS; INTERPRETATION 1 SECTION 1.01 Defined Terms 1 SECTION 1.02 Interpretation 9 ARTICLE II PURCHASE AND SALE 10 SECTION 2.01 Purchase an |
|
| April 27, 2022 |
EX-15.1 10 exhibit151-exx151consentk.htm EX-15.1 Exhibit 15.1 Erytech Pharma S.A. Head office: 60, avenue Rockefeller - 69008 - Lyon Consent of independent Registered Public Accounting Firm The Board of Directors, We consent to the incorporation by reference in the registration statements Nos. 333-255900, 333-239429, 333-232670 and 333-222673 on Form S-8 and Nos. 333-248953 and 333-259690 on Form |
|
| April 27, 2022 |
Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 |
|
| April 27, 2022 |
Exhibit 4.33 ERYTECH PHARMA Public limited company (société anonyme) with share capital of €2.641.238,90 Headquarters: 60, avenue Rockefeller, 69008 Lyon Lyon Trade Register 479 560 013 TERMS AND CONDITIONS DETACHABLE ORDINARY STOCK SUBSCRIPTION WARRANTS REFERRED TO AS BSA2021 Adopted by the Board of Directors on July, 27th 2021 1 SUMMARY 1 GENERAL PROVISIONS 3 2 DEFINITIONS 3 3 NUMBER OF BSA2021 |
|
| April 27, 2022 |
2021 Free Share Plan (English translation) Exhibit 4.32 ERYTECH PHARMA Public limited company (soci?t? anonyme) with share capital of ? 2.641.238,90 Headquarters: 60, avenue Rockefeller, 69008 Lyon Lyon Trade Register 479 560 013 TERMS AND CONDITIONS OF THE FREE SHARE ALLOCATION PLAN (AGA2021 PLAN) Adopted by the Board of Directors on July 27th, 2021 SUMMARY 1 GENERAL PROVISIONS 3 2 PURPOSE OF THE TERMS & CONDITIONS 3 3 DEFINITIONS 3 4 SHA |
|
| April 27, 2022 |
Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the ordinary shares, the American Depositary Shares and the bylaws of Erytech Pharma S.A. (?Erytech? or the ?Company?) is a summary and does not purport to be complete. This summary is subject to and qualified in its entirety by reference to the complete text |
|
| April 27, 2022 |
Exhibit 12.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULES 13a - 14(a) AND 15(d)-14(a) as ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Eric Soyer, certify that: 1. I have reviewed this annual report on Form 20-F of ERYTECH Pharma S.A. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of |
|
| April 27, 2022 |
) of the registrant (English translation) EX-1.1 2 exhibit11-exx112021bylaws.htm EX-1.1 Exhibit 1.1 ERYTECH PHARMA Corporation with a board of directors and a capital of 3,101,855.30 Euros Head office: 60 avenue Rockefeller (69008) Lyon 479 560 013 Lyon Trade and Companies Register BYLAWS /s/Gil Beyen Updated on 17 December 2021 True copy certified by the Chief Executive Officer Gil BEYEN 1 SECTION I FORM - NAME - CORPORATE PURPOSE HEAD O |
|
| April 27, 2022 |
Exhibit 4.31 ERYTECH PHARMA Public limited company (soci?t? anonyme) with share capital of ? 2.641.238,90 Headquarters: 60, avenue Rockefeller, 69008 Lyon Lyon Trade Register 479 560 013 TERMS AND CONDITIONS OF THE 2021 STOCK OPTION PLAN Adopted by the Board of Directors on July 27th, 2021 1 SUMMARY 1 Purposes of the Plan 3 2 Definitions 3 3 Shares Subject to the Plan 5 4 Administration of the Pla |
|
| April 27, 2022 |
Exhibit 12.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULES 13a-14(a) and 15d - 14(a) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Gil Beyen, certify that: 1. I have reviewed this annual report on Form 20-F of ERYTECH Pharma S.A. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a m |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) |
|
| April 25, 2022 |
ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent Exhibit 99.1 PRESS RELEASE ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent ? Catalent acquired ERYTECH?s U.S. cell therapy manufacturing facility for a total consideration of USD 44.5 million ? ERYTECH and Catalent to enter into a long-term supply agreement for clinical and commercial supply of eryaspase (GRASPA?) ? Transaction expected to reduce opera |
|
| March 15, 2022 |
6-K 1 eryp6-kx03112022.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address |
|
| March 15, 2022 |
EX-99.1 2 ex-991eryp6xkx03112022.htm EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021 Conference call and webcast on Tuesday, March 14, 2022 at 8:30am EDT / 1:30pm CET ▪Progress towards seeking approval of GRASPA® for the treatment of ALL patients with hypersensitivity to pegylated asparaginase; BLA almost ready to submit p |
|
| February 15, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including additional amendments thereto) with respect to the Ordinary Shares, nominal value ?0.10 per share, of ERYTECH Pharma S.A. This Joint Filing Agreement shall |
|
| February 15, 2022 |
EYRYY / Erytech Pharma / ARMISTICE CAPITAL, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 ERYTECH Pharma S.A. (Name of Issuer) Ordinary Shares, nominal value ?0.10 per share (Title of Class of Securities) 29604W108 (CUSIP Number |
|
| February 10, 2022 |
ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases Exhibit 99.1 PRESS RELEASE ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases Cambridge, MA (U.S.) and Lyon (France), February 8, 2022 ? ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the allowance of a US |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2022 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive offic |
|
| January 27, 2022 |
EX-99.1 2 ex-991eryp6xkx01242022.htm EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI ▪Interim results from the Phase 1 rESPECT trial of eryaspase plus mFOLFIRINOX as first-line treatment for advanced pancreatic cancer patients, presented in a poster presentation, confirm good safety profile and demonst |
|
| January 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2022 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office |
|
| December 16, 2021 |
Exhibit 10.1 FORM OF INVESTOR SUBSCRIPTION AGREEMENT Erytech Pharma S.A. B?timent Ad?nine 60 Avenue Rockefeller 69008 Lyon France The undersigned (the ?Investor?) hereby confirms its agreement with you as follows: 1. This Subscription Agreement (the ?Agreement?) is made as of the date set forth below between Erytech Pharma S.A., a societ? anonyme organized under the laws of France, with a share ca |
|
| December 16, 2021 |
Exhibit 10.2 THESE TERMS AND CONDITIONS OF THE WARRANTS DO NOT CONSTITUTE A CERTIFICATE REPRESENTING THE WARRANTS. TERMS AND CONDITIONS OF THE WARRANTS Erytech Pharma S.A., a soci?t? anonyme organized under the laws of France and registered with the Register of Commerce and Companies (Registre du Commerce et des Soci?t?s) of Lyon under number 479 560 013, with a registered capital of Euros [2 794 |
|
| December 16, 2021 |
ERYTECH Announces $7.85 Million Registered Direct Offering Exhibit 99.2 PRESS RELEASE ERYTECH Announces $7.85 Million Registered Direct Offering Lyon (France) and Cambridge, MA (U.S.), December 14, 2021 ? ERYTECH Pharma (Nasdaq & Euronext: ERYP) (the ?Company?), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has entered into a definitiv |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive offic |
|
| December 16, 2021 |
Exhibit 10.3 PLACEMENT AGENCY AGREEMENT December 14, 2021 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this ?Agreement?), ERYTECH Pharma S.A., a soci?t? anonyme organized under the laws of France and registered with the Register of Commerce and Companies (Registre du Commerce et des Soci?t?s) of |
|
| December 16, 2021 |
Exhibit 99.1 ERYTECH ANNOUNCES PRESENTATION OF RESULTS OF EXPANDED ACCESS PROGRAM IN ALL AT 2021 ASH ANNUAL MEETING AND ACCEPTANCE OF TWO ABSTRACTS AT ASCO GI ERYTECH Announces Presentation of Results of Expanded Access Program in ALL at 2021 ASH Annual Meeting and Acceptance of Two Abstracts at ASCO GI ? Full results of the Expanded Access Program in ?Double Allergic? acute lymphoblastic leukemia |
|
| December 16, 2021 |
Table of Contents Filed pursuant to Rule 424(b)(5) Registration File No. 333-259690 PROSPECTUS SUPPLEMENT (To prospectus dated September 29, 2021) 769,608 Units, Each Consisting of Four American Depositary Shares Representing Four Ordinary Shares and Three Warrants, Each to Purchase One Ordinary Share $10.20 per Unit We are offering 769,608 Units, with each Unit consisting of four American Deposit |
|
| November 30, 2021 |
6-K 1 eryp6-kx11292021.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Addre |
|
| November 30, 2021 |
EX-99.1 2 ex-991eryp6xkx11292021.htm EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors ▪Prior treatment with methioninase shown to sensitize certain solid tumor types to asparaginase-based treatment ▪New patent granting adding to portfolio of 310 granted patents in 16 patent families Cambridge, MA (U.S.) and |
|
| November 16, 2021 |
EX-99.-1 2 ex-991eryp6xkx11152021.htm EX-99.-1 Exhibit 99.1 PRESS RELEASE ERYTECH Provides Business and Financial Update for the Third Quarter of 2021 Conference call and webcast on Tuesday, November 16, 2021 at 8:30am EST / 2:30pm CET ▪Progress towards seeking approval of eryaspase for the treatment of ALL patients who experienced hypersensitivity to pegylated asparaginase; Fast Track designation |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive offic |
|
| October 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office |
|
| October 25, 2021 |
Exhibit 99.1 PRESS RELEASE ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer ▪The trial did not meet its primary endpoint of overall survival ▪The prespecified subgroup of patients treated with eryaspase and an irinotecan-based chemotherapy demonstrated an interesting trend of survival benefit, which merits further investiga |
|
| October 5, 2021 |
6-K 1 eryp6-kx10042021.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Addres |
|
| October 5, 2021 |
Exhibit 99.1 PRESS RELEASE ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer ▪No dose-limiting toxicity (DLT) reported in first two dose cohorts, leading to declaration of the maximum tolerated dose (MTD) at 100 U/kg ▪Encouraging clinical activity observed in first patients Lyon (France) and Cambridge, MA (U.S.) |
|
| September 28, 2021 |
60 Avenue Rockefeller 69008 Lyon France 60 Avenue Rockefeller 69008 Lyon France September 28, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Laura Crotty Re: ERYTECH Pharma S.A. Registration Statement on Form F-3 Filed September 21, 2021 File No. 333-259690 Acceleration Request Requested Date: September 29, 2021 Requested Time: 4:00 p.m. Eastern T |
|
| September 21, 2021 |
6-K 1 eryp6-kx09202021.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Addr |
|
| September 21, 2021 |
As filed with the Securities and Exchange Commission on September 21, 2021 Table of Contents As filed with the Securities and Exchange Commission on September 21, 2021 Registration No. |
|
| September 21, 2021 |
Bylaws (statuts) of the Registrant (English translation). EX-4.1 2 d133191dex41.htm EX-4.1 Exhibit 4.1 ERYTECH PHARMA Corporation with a board of directors and a capital of 2,772,904.70 Euros Head office: 60 avenue Rockefeller (69008) Lyon 479 560 013 Lyon Trade and Companies Register BYLAWS Updated on 31 August 2021 True copy certified by the Chief Executive Officer Gil BEYEN Page 1 of 15 SECTION I FORM - NAME - CORPORATE PURPOSE HEAD OFFICE - DURATION |
|
| September 21, 2021 |
Exhibit 99.1 PRESS RELEASE ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021 Conference call and webcast on Tuesday, September 21, 2021 at 8:30am EST/ 2:30pm CET ?TRYbeCA-1, Phase 3 trial of eryaspase in second-line metastatic pancreatic cancer fully enrolled since January 2021; on track for final results in Q4 2021 ?Fast Track designation received for eryas |
|
| September 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive offi |
|
| September 20, 2021 |
I.CERTIFICATION OF THE PERSON RESPONSIBLE FOR THE HALF-YEAR FINANCIAL REPORT “I hereby certify that, to my knowledge, the condensed financial statements for the six-month period ended June 30, 2021 were prepared in accordance with applicable accounting principles and give a fair view of assets, financial position and results of the Company and all companies included in the scope of consolidation, |
|
| July 30, 2021 |
ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL EX-99.1 2 ex-991eryp6xkx07292021.htm EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL ▪Fast Track designation for eryaspase underscores the need for new treatment options for patients who developed hypersensitivity reactions to pegylated asparaginase Cambridge, MA (U.S.) and Lyon (France), July 29, 2021 – ERYTECH Pharma (Nasdaq |
|
| July 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) I |
|
| July 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) I |
|
| July 26, 2021 |
ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients EX-99.1 2 ex-991eryp6xkx07212021.htm EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients ▪Meeting with the U.S. FDA clarified steps and requirements for the submission of a Biologics License Application (BLA) for eryaspase for the treatment of ALL patients who developed hypersensitivity reactions to prior asparaginase therapy, suppor |
|
| June 29, 2021 |
REPORT - ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 25, 2021 Exhibit 99.1 PRESS RELEASE REPORT - ERYTECH?S COMBINED SHAREHOLDERS? MEETING ON JUNE 25, 2021 Lyon (France), June 25, 2021 ? ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP) announced that its 2021 Annual General Meeting was held in Lyon on Friday, June 25, 2021. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: - Approval of the an |
|
| June 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) I |
|
| May 26, 2021 |
EX-99.1 2 ex-991eryp6xkx05252021.htm EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 25, 2021 Live webcast of the Shareholders’ Meeting Availability of the preparatory documents for the Shareholders’ Meeting Lyon (France), May 25, 2020 – Erytech Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies b |
|
| May 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) In |
|
| May 7, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) In |
|
| May 7, 2021 |
As filed with the Securities and Exchange Commission on May 7, 2021 Registration No. |
|
| May 7, 2021 |
EX-99.1 2 ex-991eryp6xkx05042021.htm EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 2021 Conference call and webcast on Wednesday, May 5, 2021 at 8:30am EST/ 2:30pm CET ▪TRYbeCA-1, Phase 3 clinical trial in 2nd line pancreatic cancer, fully enrolled, and on track for final results in Q4 2021 ▪Pre-BLA meeting with FDA reque |
|
| May 5, 2021 |
Table of Contents Filed pursuant to Rule 424(b)(5) Registration File No. 333-248953 PROSPECTUS SUPPLEMENT (To prospectus dated October 9, 2020) 1,034,483 Units, Each Consisting of Four American Depositary Shares Representing Four Ordinary Shares and Three Warrants, Each to Purchase One Ordinary Share $29.00 per Unit We are offering 1,034,483 Units, with each Unit consisting of four American Deposi |
|
| May 3, 2021 |
Exhibit 99.1 PRESS RELEASE ERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details of its 2021 Q1 conference call Publication of Q1 2021 results on 4 May 2021 after market close Lyon (France) and Cambridge, MA (U.S.), April 29, 2021 ? ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic dr |
|
| May 3, 2021 |
ERYTECH Announces $30.0 Million Registered Direct Offering EX-99.1 6 d180388dex991.htm EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Announces $30.0 Million Registered Direct Offering Lyon (France) and Cambridge, MA (U.S.), April 29, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP) (the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced tha |
|
| May 3, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) In |
|
| May 3, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) |
|
| May 3, 2021 |
Table of Contents Filed pursuant to Rule 424(b)(5) Registration File No. 333-248953 PROSPECTUS SUPPLEMENT (To prospectus dated October 9, 2020) 1,034,483 Units, Each Consisting of Four American Depositary Shares Representing Four Ordinary Shares and Three Warrants, Each to Purchase One Ordinary Share $29.00 per Unit We are offering 1,034,483 Units, with each Unit consisting of four American Deposi |
|
| May 3, 2021 |
ERYTECH Announces $30.0 Million Registered Direct Offering Exhibit 99.2 PRESS RELEASE ERYTECH Announces $30.0 Million Registered Direct Offering Lyon (France) and Cambridge, MA (U.S.), April 29, 2021 ? ERYTECH Pharma (Nasdaq & Euronext: ERYP) (the ?Company?), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has entered into definitive agr |
|
| May 3, 2021 |
Placement Agency Agreement, dated as of April 29, 2021 EX-10.3 5 d180388dex103.htm EX-10.3 Exhibit 10.3 PLACEMENT AGENCY AGREEMENT April 29, 2021 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), ERYTECH Pharma S.A., a société anonyme organized under the laws of France and registered with the Register of Commerce and Companies (Registre |
|
| May 3, 2021 |
Form of Subscription Agreement, dated as of April 29, 2021 EX-10.1 3 d180388dex101.htm EX-10.1 Exhibit 10.1 FORM OF INVESTOR SUBSCRIPTION AGREEMENT Erytech Pharma S.A. Bâtiment Adénine 60 Avenue Rockefeller 69008 Lyon France The undersigned (the “Investor”) hereby confirms its agreement with you as follows: 1. This Subscription Agreement (the “Agreement”) is made as of the date set forth below between Erytech Pharma S.A., a societé anonyme organized under |
|
| May 3, 2021 |
Terms and Conditions of the Warrants, dated as of April 29, 2021 EX-10.2 4 d180388dex102.htm EX-10.2 Exhibit 10.2 TERMS AND CONDITIONS OF THE WARRANTS Erytech Pharma S.A., a société anonyme organized under the laws of France and registered with the Register of Commerce and Companies (Registre du Commerce et des Sociétés) of Lyon under number 479 560 013, with a registered capital of Euros 2 164 648,90 and having its registered office at 60 Avenue Rockefeller, 6 |
|
| April 21, 2021 |
ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL Exhibit 99.1 PRESS RELEASE ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL ?ERYTECH invited by FDA to request a pre-BLA meeting ?First step in the marketing approval process with the FDA for eryaspase for the treatment of hypersensitive ALL patients based on the positive results of the NOPHO-sponsored Phase 2 clinical trial Lyon (France) and Cambridge, MA (U.S.) |
|
| April 21, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) |
|
| April 19, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) |
|
| April 19, 2021 |
Exhibit 99.1 PRESS RELEASE ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer ?No dose-limiting toxicity reported in the first dose cohort ?Encouraging clinical activity observed in first patients ?Trial will be escalated to the next dose Lyon (France) and Cambridge, MA (U.S.), April 19, 2021 ? ERYTECH Pharma (Nasdaq |
|
| March 10, 2021 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated March 9, 2021 with respect to the Ordinary Shares, nominal value €0.10 per share ERYTECH Pharma S.A., a French corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 ERYTECH Pharma S.A. (Name of Issuer) Ordinary Shares, nominal value €0.10 per share (Title of Class of Securities) 29604W108 (CUSIP Number) |
|
| March 9, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant?s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) |
|
| March 9, 2021 |
Exhibit 99.1 PRESS RELEASE ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2020 Conference call and webcast on Tuesday, March 9, 2021 at 8:30am EST/ 2:30pm CET ▪Strong execution and achievement of key milestones in challenging year 2020 ▪Four clinical programs with lead product candidate eryaspase expected to report results and/or regulatory milestones in 2021. Two |
|
| March 8, 2021 |
Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 |
|
| March 8, 2021 |
EX-15.1 11 exhibit151-exx151consentk.htm EX-15.1 Exhibit 15.1 Consent of independent Registered Public Accounting Firm The Board of Directors, We consent to the incorporation by reference in the registration statements nos. 333-239429, 333-232670 and 333-222673 on Form S-8 and no. 333-248953 on Form F-3 of Erytech Pharma S.A. of our report dated March 8, 2021, with respect to the consolidated stat |
|
| March 8, 2021 |
Exhibit 4.30 AGREEMENT FOR THE ISSUANCE OF AND SUBSCRIPTION TO WARRANTS GIVING ACCESS TO NOTES CONVERTIBLE INTO NEW AND/OR EXISTING SHARES WITH SHARE SUBSCRIPTION WARRANTS ATTACHED ("BONS D'EMISSION D'OBLIGATIONS CONVERTIBLES EN ACTIONS NOUVELLES ET/OU EXISTANTES AVEC BONS DE SOUSCRIPTION D'ACTIONS ATTACHES") BETWEEN ERYTECH PHARMA SA AND EUROPEAN HIGH GROWTH OPPORTUNITIES SECURITIZATION FUND DATE |
|
| March 8, 2021 |
Exhibit 4.27 ERYTECH PHARMA Public limited company (soci?t? anonyme) with share capital of ?1,795,611.50 Headquarters: 60, avenue Rockefeller, 69008 Lyon Lyon Trade Register 479 560 013 TERMS AND CONDITIONS OF THE 2020 STOCK OPTION PLAN Adopted by the Board of Directors on July 28th, 2020 1 SUMMARY 1 Purpose of the Plan 3 2 Definitions 3 3 Shares Subject to the Plan 5 4 Administration of the Plan |
|
| March 8, 2021 |
Exhibit 12.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULES 13a - 14(a) AND 15(d)-14(a) as ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Eric Soyer, certify that: 1. I have reviewed this annual report on Form 20-F of ERYTECH Pharma S.A. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of |
|
| March 8, 2021 |
2020 Free Share Plan (English translation) EX-4.28 5 exhibit428-exx42820reesha.htm EX-4.28 Exhibit 4.28 ERYTECH PHARMA Public limited company (société anonyme) with share capital of €1,795,611.50 Headquarters: 60, avenue Rockefeller, 69008 Lyon Lyon Trade Register 479 560 013 TERMS AND CONDITIONS OF THE FREE SHARE ALLOCATION PLAN (AGA2020 PLAN) Adopted by the Board of Directors on July 28th, 2020 SUMMARY 1 GENERAL PROVISIONS 3 2 PURPOSE OF |
|
| March 8, 2021 |
EX-4.29 6 exhibit429-exx4292020bsap.htm EX-4.29 Exhibit 4.29 ERYTECH PHARMA Public limited company (société anonyme) with share capital of €1,795,611.50 Headquarters: 60, avenue Rockefeller, 69008 Lyon Lyon Trade Register 479 560 013 TERMS AND CONDITIONS DETACHABLE ORDINARY STOCK SUBSCRIPTION WARRANTS REFERRED TO AS BSA2020 Adopted by the Board of Directors on July, 28th 2020 1 SUMMARY 1 GENERAL P |
|
| March 8, 2021 |
Bylaws (statuts) of the Registrant (English translation) Exhibit 1.1 ERYTECH PHARMA Corporation with a board of directors and a capital of 2,118,641.60 Euros Head office: 60 avenue Rockefeller (69008) Lyon 479 560 013 Lyon Trade and Companies Register BYLAWS /s/Gil Beyen Updated on 5 March 2021 True copy certified by the Chief Executive Officer Gil BEYEN 1 SECTION I FORM - NAME - CORPORATE PURPOSE HEAD OFFICE - DURATION ARTICLE 1. FORM The Company was e |
|
| March 8, 2021 |
EX-2.3 3 exhibit23-exx23descriptio.htm EX-2.3 Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the ordinary shares, the American Depositary Shares and the bylaws of Erytech Pharma S.A. (“Erytech” or the “Company”) is a summary and does not purport to be complete. This summary is subject to and qualified in i |
|
| March 8, 2021 |
Exhibit 12.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULES 13a-14(a) and 15d - 14(a) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Gil Beyen, certify that: 1. I have reviewed this annual report on Form 20-F of ERYTECH Pharma S.A. (the ?Company?); 2. Based on my knowledge, this report does not contain any untrue statement of a m |
|
| March 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| February 8, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive offic |
|
| February 8, 2021 |
ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis EX-99.1 2 ex-991eryp6xkx02082021.htm EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis •The Independent Data Monitoring Committee (IDMC) recommends trial to continue to final analysis, expected in Q4 2021 •No safety issues identified, consistent with observations in previous IDMC reviews Lyon (France) and Cambridge, M |
|
| January 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 ERYTECH Pharma S.A. (Name of Issuer) Ordinary Shares, nominal value €0.10 per share (Title of Class of Securities) 29604W108 (CUSIP Number) JAMES KRATK |
|
| January 27, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office |
|
| January 27, 2021 |
ERYTECH Highlights 2021 Milestones and Provides Update on Cash Position Exhibit 99.1 PRESS RELEASE ERYTECH Highlights 2021 Milestones and Provides Update on Cash Position ▪Strong execution and achievement of key milestones in challenging year 2020 ▪Four clinical programs with lead product candidate eryaspase expected to report results and/or regulatory milestones in 2021: –TRYBeCA-1, Phase 3 in 2L advanced pancreatic cancer, expected to report top-line results, potent |
|
| January 15, 2021 |
EX-99.1 2 ex-991eryp6xkx01142021.htm EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer •Trial to evaluate safety of eryaspase in combination with FOLFIRINOX for the first-line treatment of pancreatic cancer •Trial in Progress (TiP) poster accepted for presentation at the American Societ |
|
| January 15, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2021 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office |
|
| January 12, 2021 |
SC 13D/A 1 sc13da307422eryp01122021.htm AMENDMENT NO. 3 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 ERYTECH Pharma S.A. (Name of Issuer) Ordinary Shares, nominal value €0.10 p |
|
| December 15, 2020 |
ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer Exhibit 99.1 PRESS RELEASE ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer •A total of 510 patients enrolled •Events required to trigger interim superiority analysis accrued •Interim superiority analysis expected in Q1 2021; final analysis in Q4 2021 Lyon (France) and Cambridge, MA (U.S.), December 14, 2020 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clin |
|
| December 15, 2020 |
Current Report of Foreign Issuer - 6-K 6-K 1 eryp6-k12142020.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2020 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Addres |
|
| December 7, 2020 |
Current Report of Foreign Issuer - 6-K 6-K 1 eryp6-kx12072020.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2020 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Addre |
|
| December 7, 2020 |
PRESS RELEASE ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting Webcast today, Monday, December 7 at 4:00 pm CET/10:00 am ET •The study confirms the potential of eryaspase as an attractive treatment option for ALL patients with hypersensitivity to PEG-asparaginase Lyon (France) and Cambridge, MA (U. |
|
| November 6, 2020 |
Current Report of Foreign Issuer - 6-K 6-K 1 d92662d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2020 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of p |
|
| November 6, 2020 |
EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Announces Abstract with Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Selected for Oral Presentation at the American Society of Hematology 2020 Annual Meeting ◾ Oral presentation to discuss findings from the Nordic Society of Paediatric Haematology and Oncology (NOPHO)-sponsored Phase 2 trial that confirm the potential of eryaspase |
|
| November 6, 2020 |
EX-99.2 Exhibit 99.2 PRESS RELEASE ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2020 Conference call and webcast on Friday, November 6 at 2:30 pm CET/8:30 am ET ◾ TRYbeCA-1 Phase 3 trial in second-line metastatic pancreatic cancer: ✓ More than 95% of the approximately 500 patients enrolled ✓ Number of events required for the interim superiority analysis h |
|
| November 3, 2020 |
Current Report of Foreign Issuer - 6-K 6-K 1 d73888d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2020 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of p |
|
| November 3, 2020 |
ERYTECH Secures €10 Million in Non-Dilutive Financing, Guaranteed by the French Government EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Secures €10 Million in Non-Dilutive Financing, Guaranteed by the French Government ◾ Approvals received from Bpifrance and Société Générale for a total of EUR 10 million in non-dilutive financing in the form of a State-Guaranteed Loan (PGE Loan) ◾ Proceeds expected to extend Company’s cash horizon to end of 2021 Lyon (France) and Cambridge, MA (U.S.), Nov |
|
| October 13, 2020 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated July 18, 2018 (including amendments thereto) with respect to the Ordinary Shares, nominal value €0.10 per share, of ERYTECH Pharma S.A. This Joint Filing A |
|
| October 13, 2020 |
SC 13D/A 1 sc13da207422eryp10132020.htm AMENDMENT NO. 2 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 ERYTECH Pharma S.A. (Name of Issuer) Ordinary Shares, nominal value €0.10 p |
|
| October 9, 2020 |
Up to $30,000,000 American Depositary Shares representing Ordinary Shares 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-248953 PROSPECTUS Up to $30,000,000 American Depositary Shares representing Ordinary Shares We have entered into a sales agreement, or the sales agreement, with Cowen and Company LLC, or Cowen, relating to the sale of American Depositary Shares, or ADSs, representing ordinary shares. In accordance with the terms of the s |
|
| October 8, 2020 |
F-3/A As filed with the Securities and Exchange Commission on October 8, 2020 Registration No. |
|
| October 7, 2020 |
CORRESP 1 filename1.htm 60 Avenue Rockefeller 69008 Lyon France October 7, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Courtney Lindsay Re: ERYTECH Pharma S.A. Registration Statement on Form F-3 Filed September 21, 2020 File No. 333-248953 Acceleration Request Requested Date: October 9, 2020 Requested Tim |
|
| October 7, 2020 |
F-3/A As filed with the Securities and Exchange Commission on October 7, 2020 Registration No. |
|
| September 22, 2020 |
Current Report of Foreign Issuer - 6-K 6-K 1 d70192d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2020 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of |
|
| September 22, 2020 |
EX-99.2 3 d70192dex992.htm EX-99.2 Exhibit 99.2 PRESS RELEASE ERYTECH establishes a financing facility with the implementation of an at-the-market program on Nasdaq with Cowen Lyon (France), September 21, 2020 - ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances in red blood cells (the |
|
| September 22, 2020 |
EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2020 Conference call and webcast on Tuesday, September 22 at 2:30 pm CET/8:30 am ET ◾ TRYbeCA-1 Phase 3 trial in second-line metastatic pancreatic cancer: ✓ More than 90% of the planned ~500 patients enrolled ✓ Fast-Track designation granted by U.S. FDA ✓ Interim superiority anal |
|
| September 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2020 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive offi |
|
| September 21, 2020 |
Sales Agreement, dated September 21, 2020, by and between the Registrant and Cowen and Company, LLC EX-1.2 Exhibit 1.2 ERYTECH PHARMA S.A. $30,000,000 AMERICAN DEPOSITARY SHARES each representing one (1) Ordinary Share SALES AGREEMENT September 21, 2020 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: ERYTECH Pharma S.A., a société anonyme organized under the laws of France and registered with the Register of Commerce and Companies (Registre du Commerce et des |
|
| September 21, 2020 |
Powers of Attorney (included on signature page). F-3 1 d19008df3.htm F-3 Table of Contents As filed with the Securities and Exchange Commission on September 21, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ERYTECH Pharma S.A. (Exact name of registrant as specified in its charter) Not Applicable (Translation of registrant’s name |
|
| September 21, 2020 |
Bylaws (statuts) of the registrant (English translation). EX-4.1 Exhibit 4.1 ERYTECH PHARMA Corporation with a board of directors and a capital of 1.830.162,10 Euros Head office: 60 avenue Rockefeller (69008) LYON 479 560 013 Lyon Trade and Companies Register BYLAWS Updated on August 31, 2020 True copy certified by the Chief Executive Officer Gil BEYEN Page 1 of 15 SECTION I FORM - NAME - CORPORATE PURPOSE HEAD OFFICE - DURATION ARTICLE 1. FORM The Compa |
|
| September 21, 2020 |
Form of American Depositary Receipt (included in Exhibit 4.2). EX-4.2 Exhibit 4.2 ERYTECH PHARMA S.A. AND THE BANK OF NEW YORK MELLON As Depositary AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Amended and Restated Deposit Agreement Dated as of May 14, 2018 TABLE OF CONTENTS ARTICLE 1. DEFINITIONS 1 SECTION 1.1. American Depositary Shares 2 SECTION 1.2. Commission 2 SECTION 1.3. Company 2 SECTION 1.4. Custodian 2 SECTION 1.5. Delisting Event 2 SECTION |
|
| September 21, 2020 |
I. CERTIFICATION OF THE PERSON RESPONSIBLE FOR THE HALF-YEAR FINANCIAL REPORT EX-99.1 Exhibit 99.1 I. CERTIFICATION OF THE PERSON RESPONSIBLE FOR THE HALF-YEAR FINANCIAL REPORT “I hereby certify that, to my knowledge, the condensed consolidated financial statements for the six-month period ended June 30, 2020 were prepared in accordance with applicable accounting principles and give a fair view of assets, financial position and results of the Company and all companies in |
|
| September 15, 2020 |
EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Announces the Hosting of a KOL Event as the TRYbeCA-1 Phase 3 Trial in Second-line Pancreatic Cancer Nears Complete Enrollment ◾ More than 450 of the planned ~500 patients enrolled ◾ Interim superiority analysis expected around year-end 2020 ◾ Call with KOL Dr. Manuel Hidalgo on September 29, 2020 at 10:00 am ET Lyon (France) and Cambridge, MA (U.S.), Sep |
|
| September 15, 2020 |
Current Report of Foreign Issuer - 6-K 6-K 1 d939688d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2020 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of |
|
| June 26, 2020 |
6-K 1 d49207d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2020 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of princ |
|
| June 26, 2020 |
ERYTECH Reports Voting Results from its Annual General Meeting Held on June 26, 2020 EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Reports Voting Results from its Annual General Meeting Held on June 26, 2020 Lyon (France) and Cambridge (U.S.), June 26, 2020 – ERYTECH Pharma (Euronext: ERYP—Nasdaq: ERYP) announced that its 2020 Annual General Meeting was held in Lyon on Friday, June 26, 2020. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor |
|
| June 25, 2020 |
As filed with the Securities and Exchange Commission on June 25, 2020 Registration No. |
|
| June 25, 2020 |
2019 BSA Subscription Plan (English translation) EX-99.4 4 d901453dex994.htm EX-99.4 Exhibit 99.4 Terms and conditions of the BSA2019 ERYTECH PHARMA Public limited company (société anonyme) with share capital of €1,794,003.50 Headquarters: 60, avenue Rockefeller, 69008 Lyon Lyon Trade Register 479 560 013 TERMS AND CONDITIONS DETACHABLE ORDINARY STOCK SUBSCRIPTION WARRANTS REFERRED TO AS BSA2019 Adopted by the Board of Directors on October the 9 |
|
| June 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2020 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) I |
|
| June 25, 2020 |
EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH extends its cash horizon by implementing a convertible bond financing Agreement with Alpha Blue Ocean and European High Growth Opportunities Securitization Fund for the issuance of zero-coupon convertible notes with share warrants attached. Lyon (France) and Cambridge, MA (U.S.), June 25, 2020, 8:00 am - ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a c |
|
| June 9, 2020 |
6-K 1 d941688d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2020 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of prin |
|
| June 9, 2020 |
EX-99.1 2 d941688dex991.htm EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Provides Update on Phase 2 Investigator Sponsored Trial of Eryaspase in Second-Line Acute Lymphoblastic Leukemia ∎ Patient enrollment completed; 50 patients in the trial ∎ Encouraging preliminary results based on interim data ∎ Unmet medical need confirmed by FDA Lyon (France) and Cambridge, MA (U.S.), June 9, 2020 – ERYTECH Ph |
|
| June 2, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2020 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) I |
|
| June 2, 2020 |
ERYTECH Announces Poster Presentations at ASCO 2020 Annual Meeting EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Announces Poster Presentations at ASCO 2020 Annual Meeting Lyon (France) and Cambridge, MA (U.S.), June 1, 2020 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announces the presentation of two posters at the American |
|
| May 26, 2020 |
EX-99.1 Exhibit 99.1 ERYTECH’S COMBINED SHAREHOLDERS’ MEETING Meeting held in closed session on June 26, 2020 Live webcast of the Shareholders’ Meeting Availability of the preparatory documents for the Shareholders’ Meeting Lyon (France), May 26, 2020 – Erytech Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating ther |
|
| May 26, 2020 |
Current Report of Foreign Issuer - 6-K 6-K 1 d933715d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2020 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of princ |
|
| May 8, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2020 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) In |
|
| May 8, 2020 |
EX-99.1 2 d927704dex991.htm EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Provides Business Update and Reports Cash Balance at End of Q1 2020 Conference call and webcast on Thursday, May 7 at 2:30 pm CET/8:30 am ET ◾ TRYbeCA-1 Phase 3 Trial: ✓ More than 75% of the planned ~500 patients enrolled ✓ Fast-Drack designation granted by U.S. FDA ✓ Trial to continue as planned after third independent safety |
|
| April 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2020 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) |
|
| April 30, 2020 |
ERYTECH Granted U.S. FDA Fast Track Designation for eryaspase in Second-Line Pancreatic Cancer EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Granted U.S. FDA Fast Track Designation for eryaspase in Second-Line Pancreatic Cancer ◾ Fast Track designation for eryaspase underscores the urgent need for potential new treatment options for patients with second line metastatic pancreatic cancer Lyon (France) and Cambridge, MA (U.S.), April 28, 2020 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinica |
|
| April 21, 2020 |
EX-99.1 2 d914562dex991.htm EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Provides Update on the TRYbeCA-1 Phase 3 Clinical Trial of Eryaspase in Second Line Pancreatic Cancer ◾ More than 75% of the planned ~500 patients enrolled in the trial ◾ Trial to continue as planned after third safety review by independent data monitoring committee ◾ Interim superiority analysis expected around year-end; final |
|
| April 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2020 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) |
|
| March 18, 2020 |
2019 Share Option Plan (English translation) Exhibit 4.22 Plan Option 2019 ERYTECH PHARMA SA 2019 STOCK OPTION PLAN In accordance with the authorization granted by the extraordinary general shareholders' meeting of June 21, 2019, the Board of Directors decided on July 31, 2019, in compliance with the provisions of Articles L. 225-177 et seq. of the French Commercial Code, to adopt the 2019 stock option plan of ERYTECH PHARMA SA, the terms an |
|
| March 18, 2020 |
2019 Free Share Plan (English translation) Exhibit 4.23 Erytech Pharma Public Limited Company with a share capital of €1,794,003.50 Headquarters: 60, avenue Rockefeller, 69008 Lyon Lyon Trade Register 479 560 013 2019 AGA Plan TERMS AND CONDITIONS OF THE FREE SHARE ALLOCATION PLAN Adopted by the Board of Directors on October the 9th, 2019 TABLE OF CONTENTS 1. GENERAL CONDITIONS14 2. PURPOSE OF THE TERMS & CONDITIONS14 3. DEFINITIONS14 4. S |
|
| March 18, 2020 |
Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of ERYTECH Pharma S.A. (“ERYTECH,” the “Company,” “we,” “us” and “our”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”). This desc |
|
| March 18, 2020 |
20-F 1 eryp-20f20191231.htm 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION |
|
| March 18, 2020 |
Exhibit 4.24 Certain information has been excluded from this exhibit because it is both not material and would likely cause competitive harm if publicly disclosed. [***] had been inserted in the text below to identify where information has been redacted. Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K and will be furnished on a supplemental basis to the Securities and Exch |
|
| March 18, 2020 |
Exhibit 13.1 Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 |
|
| March 18, 2020 |
Exhibit 15.1 KPMG Audit 51 rue de Saint-Cyr CS 60409 69338 Lyon Cedex 9 France Téléphone : Télécopie : Site internet : +33 (0)4 37 64 76 00 +33 (0)4 37 64 76 09 www.kpmg.fr Erytech Pharma S.A. Head office: 60 avenue Rockefeller - 69008 - Lyon Consent of independent Registered Public Accounting Firm The Board of Directors, We consent to the incorporation by reference in the registration statements |
|
| March 18, 2020 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Gil Beyen, certify that: 1. I have reviewed this annual report on Form 20-F of ERYTECH Pharma S.A. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a mat |
|
| March 18, 2020 |
Exhibit 4.25 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is effective as of April 1, 2019 (the “Effective Date”) by and between ERYTECH Pharma, Inc., (the “Company”), and Gil Beyen (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”). R E C I T A L S WHEREAS, Executive currently serves as Chief Executive Office |
|
| March 18, 2020 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Eric Soyer, certify that: 1. I have reviewed this annual report on Form 20-F of ERYTECH Pharma S.A. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a ma |
|
| March 17, 2020 |
ERYTECH Announces the Appointment of Dr. Melanie Rolli to its Board of Directors EX-99.1 2 d898979dex991.htm EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Announces the Appointment of Dr. Melanie Rolli to its Board of Directors Lyon (France) and Cambridge, MA (U.S.), March 16, 2020 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announc |
|
| March 17, 2020 |
6-K 1 d898979d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2020 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of pri |
|
| March 17, 2020 |
EX-99.2 3 d898979dex992.htm EX-99.2 Exhibit 99.2 PRESS RELEASE ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2019 Conference call and webcast on Tuesday, March 17 at 1:30 pm CET/8:30 am ET ◾ More than two-thirds of the expected number of patients have been enrolled in the TRYbeCA-1 Phase 3 clinical trial ◾ Cash position of €73.2 million ($82.2 million) at the end |
|
| February 6, 2020 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2020 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive o |
|
| February 6, 2020 |
Exhibit 99.1 I. BUSINESS REPORT 1.1 COMPANY OVERVIEW Erytech is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBCs, Erytech is developing a pipeline of product |
|
| November 8, 2019 |
EYRYY / Erytech Pharma 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2019 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive offic |
|
| November 8, 2019 |
EX-99.1 Exhibit 99.1 PRESS RELEASE ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2019 Conference call and webcast on Friday, November 8 at 2:30 pm CET/8:30 am ET ◾ TRYbeCA1, Phase 3 trial of eryaspase in second line pancreatic cancer: - positive safety review by independent data monitoring committee - opened for patient enrollment in the United States - fi |
|
| September 26, 2019 |
EYRYY / Erytech Pharma 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2019 Commission File Number: 001-38281 ERYTECH Pharma S.A. (Translation of registrant’s name into English) 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive offi |
